• Something wrong with this record ?

The Peptidic GHS-R antagonist [D-Lys(3)]GHRP-6 markedly improves adiposity and related metabolic abnormalities in a mouse model of postmenopausal obesity

L. Maletínská, R. Matyšková, J. Maixnerová, D. Sýkora, M. Pýchová, A. Spolcová, M. Blechová, J. Drápalová, Z. Lacinová, M. Haluzík, B. Zelezná,

. 2011 ; 343 (1-2) : 55-62. [pub] 20110617

Language English Country Ireland

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc12022477

It was demonstrated that estrogen deficiency and consuming high fat (HF) diet enhanced orexigenic activity of ghrelin. Therefore, we hypothesized that antagonizing of ghrelin action would attenuate food intake and body weight in mice obese both from ovariectomy (OVX) and feeding a HF diet. Ghrelin receptor antagonist [D-Lys(3)]GHRP-6 after seven days of subcutaneous treatment markedly decreased food intake in OVX mice fed both HF and standard diets; furthermore, it reduced body weight and blood glucose, insulin and leptin, and increased β-hydroxybutyrate level and uncoupling-protein-1 mRNA in brown adipose tissue. Pair-feeding revealed that effect of [D-Lys(3)]GHRP-6 was primary anorexigenic. Estrogen supplementation reduced anorexigenic effects of [D-Lys(3)]GHRP-6. OVX [D-Lys(3)]GHRP-6 treatment in mice on HF diet resulted in markedly increased circulating level and liver expression of a major metabolic regulator, fibroblast growth factor 21. Our data suggest that ghrelin antagonists could be especially beneficial in individuals with common obesity combined with estrogen deficiency.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12022477
003      
CZ-PrNML
005      
20250521153936.0
007      
ta
008      
120806s2011 ie f 000 0#eng||
009      
AR
024    7_
$a 10.1016/j.mce.2011.06.006 $2 doi
035    __
$a (PubMed)21704671
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Maletínská, L $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic. maletin@uochb.cas.cz
245    14
$a The Peptidic GHS-R antagonist [D-Lys(3)]GHRP-6 markedly improves adiposity and related metabolic abnormalities in a mouse model of postmenopausal obesity / $c L. Maletínská, R. Matyšková, J. Maixnerová, D. Sýkora, M. Pýchová, A. Spolcová, M. Blechová, J. Drápalová, Z. Lacinová, M. Haluzík, B. Zelezná,
520    9_
$a It was demonstrated that estrogen deficiency and consuming high fat (HF) diet enhanced orexigenic activity of ghrelin. Therefore, we hypothesized that antagonizing of ghrelin action would attenuate food intake and body weight in mice obese both from ovariectomy (OVX) and feeding a HF diet. Ghrelin receptor antagonist [D-Lys(3)]GHRP-6 after seven days of subcutaneous treatment markedly decreased food intake in OVX mice fed both HF and standard diets; furthermore, it reduced body weight and blood glucose, insulin and leptin, and increased β-hydroxybutyrate level and uncoupling-protein-1 mRNA in brown adipose tissue. Pair-feeding revealed that effect of [D-Lys(3)]GHRP-6 was primary anorexigenic. Estrogen supplementation reduced anorexigenic effects of [D-Lys(3)]GHRP-6. OVX [D-Lys(3)]GHRP-6 treatment in mice on HF diet resulted in markedly increased circulating level and liver expression of a major metabolic regulator, fibroblast growth factor 21. Our data suggest that ghrelin antagonists could be especially beneficial in individuals with common obesity combined with estrogen deficiency.
650    _2
$a hnědá tuková tkáň $x metabolismus $7 D002001
650    _2
$a adipozita $x účinky léků $7 D050154
650    _2
$a zvířata $7 D000818
650    _2
$a chování zvířat $x účinky léků $7 D001522
650    _2
$a tělesná hmotnost $x účinky léků $7 D001835
650    _2
$a dieta s vysokým obsahem tuků $7 D059305
650    _2
$a přijímání potravy $x účinky léků $7 D004435
650    _2
$a estrogeny $x aplikace a dávkování $x nedostatek $7 D004967
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a ghrelin $x metabolismus $7 D054439
650    _2
$a přenašeč glukosy typ 1 $x genetika $x metabolismus $7 D051272
650    _2
$a lidé $7 D006801
650    _2
$a iontové kanály $x genetika $x metabolismus $7 D007473
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a mitochondriální proteiny $x genetika $x metabolismus $7 D024101
650    _2
$a modely u zvířat $7 D023421
650    _2
$a pohybová aktivita $x účinky léků $7 D009043
650    _2
$a obezita $x patofyziologie $7 D009765
650    _2
$a oligopeptidy $x farmakologie $7 D009842
650    _2
$a ovarektomie $7 D010052
650    _2
$a PPAR alfa $x genetika $x metabolismus $7 D047493
650    _2
$a postmenopauza $x metabolismus $7 D017698
650    _2
$a receptory ghrelinu $x antagonisté a inhibitory $x genetika $x metabolismus $7 D054440
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Matyšková, R
700    1_
$a Maixnerová, J
700    1_
$a Sýkora, D
700    1_
$a Pýchová, M
700    1_
$a Spolcová, A
700    1_
$a Blechová, Miroslava $7 xx0332173
700    1_
$a Drápalová, J
700    1_
$a Lacinová, Z
700    1_
$a Haluzík, M
700    1_
$a Zelezná, B
773    0_
$w MED00003387 $t Molecular and cellular endocrinology $x 1872-8057 $g Roč. 343, č. 1-2 (2011), s. 55-62
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21704671 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120806 $b ABA008
991    __
$a 20250521153934 $b ABA008
999    __
$a ok $b bmc $g 944390 $s 779774
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 343 $c 1-2 $d 55-62 $e 20110617 $i 1872-8057 $m Molecular and cellular endocrinology $n Mol Cell Endocrinol $x MED00003387
LZP    __
$a Pubmed-20120806/12/01

Find record

Citation metrics

Archiving options